First human test for new IPF inhaler begins
NCT ID NCT06181370
Summary
This is the first study in people to test the safety of an experimental inhaled medicine called AGMB-447 for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The study will enroll healthy volunteers and people with IPF to see how their bodies handle single and multiple doses of the drug, which is breathed in through a nebulizer. The main goal is to check for side effects and see how the drug moves through the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medicines Evaluation Unit Ltd. an IQVIA business
RECRUITINGManchester, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.